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Abstract
Effects of benzodiazepines on postmortem opioid parent and parent/metabolite blood 
concentration ratios were determined for fentanyl-, hydrocodone-, methadone-, or oxycodone-
related accidental deaths. These opioids are partially metabolized by the CYP3A4 enzyme system, 
which is also affected by diazepam and alprazolam. Opioid/metabolite combinations examined 
were as follows: fentanyl/norfentanyl, hydrocodone/dihydrocodeine, methadone/EDDP, and 
oxycodone/oxymorphone. Parent opioid concentrations were analyzed for 877 deaths. Parent/
metabolite concentration ratios were analyzed for 349 deaths, excluding cases with co-intoxicants 
present known to interfere with opioid elimination. Alprazolam in combination with diazepam 
significantly decreased median hydrocodone concentrations by 48% (p = 0.01) compared to 
hydrocodone alone. The methadone parent/metabolite concentration ratio was reduced by 35% in 
the presence of diazepam compared to methadone alone (p = 0.03). Benzodiazepines did not 
statistically significantly affect fentanyl or oxycodone concentrations. Possible factors affecting 
opioid concentrations and possible toxicity development, including any differential effects on 
specific opioids, should continue to be explored.
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Drug-related deaths are a growing problem and a serious public health concern (1). The 
CDC reported 27,153 overdose deaths nationally in 2008, with 73.8% involving one or more 
prescription drugs (2). Seventy-eight percent of drug poisoning deaths in 2010 were 
unintentional, and since 2009, more people have died annually from overdoses than from 
motor vehicle accidents (3). From 1999 to 2010, drug overdose deaths have more than 
doubled and those involving an opioid more than quadrupled (4).
Opioid-related deaths typically involve multiple drugs, including benzodiazepines, cocaine, 
and heroin, among others (5). Benzodiazepines in particular have been identified in many 
deaths involving fentanyl, oxycodone, methadone, and morphine (6–14). Several studies 
have reported evidence of concomitant benzodiazepine consumption in 11% to 86% of 
opioid-related deaths (5–7,12,13,15–25).
Opioids have many physiological effects including alterations in body temperature, sedation, 
respiratory depression, and euphoria. When taken with opioids, benzodiazepines are 
typically characterized as reinforcer drugs that augment the opioids’ rewarding effects (26). 
Due to the frequency in which benzodiazepines are identified in opioid-associated fatalities, 
it is important to examine potential drug–drug interactions that might contribute to mortality. 
Theoretically, pharmacologic drug interactions may occur with opioids and benzodiazepines 
through additive sedative and respiratory depressant effects (26). Pharmacokinetic 
interactions may result from a drug's inhibition or induction of, or competition with, an 
enzyme responsible for metabolizing another drug.
Several opioids involved in fatalities are metabolized by more than one cytochrome P450 
(CYP450) enzyme. Fentanyl is metabolized primarily by the CYP3A4 enzyme to a single 
major inactive metabolite, norfentanyl (27,28). Hydrocodone is mainly metabolized by 
CYP3A4 to an inactive metabolite, norhydroco-done; CYP2D6 metabolism is a minor 
pathway yielding a potent metabolite, hydromorphone (29,30). A third metabolite, dihydro-
codeine, is formed from hydrocodone but less is known about this metabolic pathway. 
However, blood dihydrocodeine concentrations might be important to measure in 
hydrocodone-related deaths because it could represent the more prevalent metabolite (31).
The metabolism of methadone is complex, and there is a lack of consensus on the relative 
contribution of individual metabolic enzymes to its biotransformation (32). It has been 
suggested that CYP2B6 is the major enzymatic pathway, with CYP2C19 and CYP3A4 
representing equal secondary pathways (32); others have indicated that CYP3A4 and 
CYP2D6 are the major metabolic pathways (33). Additionally, methadone is available as a 
racemic mixture and different CYP enzymes are thought to preferentially metabolize each 
enantiomer (32). The major inactive metabolite formed during methadone metabolism is 2-
ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) (32). Oxycodone is metabolized 
by the CYP3A4 and CYP2D6 enzymes (29,34). The major metabolic pathway is by 
CYP3A4 to form a less active metabolite, noroxycodone. The minor pathway, catalyzed by 
the CYP2D6 enzyme, produces a more potent metabolite, oxymorphone. Oxymorphone is 
most frequently measured by the West Virginia Office of the Chief Medical Examiner as part 
of oxycodone death investigations.
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Alprazolam and diazepam are two benzodiazepines commonly involved in accidental opioid 
deaths (16). Alprazolam is primarily metabolized by CYP3A4 (35). Diazepam is 
metabolized by both CYP3A4 and CYP2C19 (35), and it has also been cited as a CYP3A4 
inhibitor (36).
In living subjects, sedative effects were observed earlier and for a longer duration when 
opioids and benzodiazepines were given together as opposed to separately, possibly 
representing a drug–drug interaction (37). Parent drug to metabolite concentration ratios of 
opioids have been determined in a few pharmaco-kinetic studies, but the results have not 
been reproducible. Inhibition of the CYP2D6 metabolic pathway of oxycodone has yielded a 
higher blood noroxycodone concentration, presumably through greater oxycodone 
metabolism by CYP3A4 (38,39). One study observed an increase in oxymorphone 
concentrations (mediated by the CYP2D6 enzyme) when the CYP3A4 pathway was 
inhibited (39); yet, another study did not observe such an increase in oxymorphone 
concentrations (40).
A limited number of human studies have examined a potential benzodiazepine and opioid 
pharmacokinetic interaction. Two small pharmacokinetic studies failed to show either a 
consistent decrease in methadone renal clearance or increased methadone blood 
concentrations over time after diazepam consumption (41,42). However, based on 
postmortem blood concentrations, one case report suggested that oxycodone's metabolism 
was reduced by concomitant clonazepam intake (8).
In death investigations of potential contributory drug toxicity, medical examiners often 
measure both parent drug and metabolite concentrations. The parent drug to metabolite ratio 
can help clarify the manner of death or differentiate an acute drug overdose from chronic 
drug use, abuse/misuse versus therapeutic drug use, or between ingestion of a parent drug 
and ingestion of an active metabolite that might also be prescribed. Parent drug to metabolite 
ratios have been described most often for methadone.
To date, very few studies have examined parent and metabolite postmortem opioid drug 
concentrations in combined opioidand benzodiazepine-related deaths. One such study 
measured concentrations of both enantiomers of methadone and its metabolite EDDP. 
Decedents were divided based on the presence of co-intoxicants, that is, other analgesics, 
benzodiazepines, and other drugs. There was no statistically significant difference in the 
ratio of methadone to EDDP concentrations across groups (10). Limitations of this study 
included a small sample size and inclusion of a number of intentional deaths (10).
West Virginia has one of the highest drug overdose death rates in the United States (3). In 
2010, the drug-related death rate was 28.3 per 100,000 population, with a 21.3% increase in 
these deaths between 2009 and 2010 (43). Of 515 West Virginia drug-related deaths in 2010, 
82.8% were considered unintentional. The top five drugs/drug classes identified in these 
deaths were opioids, benzodiazepines, antidepressants, alcohol, and cocaine (43). The 
opioids most commonly identified in the West Virginia drug-related deaths (2005–2010) 
were fentanyl, hydro-codone, methadone, and oxycodone (unpublished data, West Virginia 
Office of the Chief Medical Examiner). In light of the frequency of combined opioid-and-
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benzodiazepine-related deaths and the relative lack of data characterizing the opioid 
concentrations in such deaths, it is important to examine the potential effects of 
benzodiazepines on opioid concentrations.
This study examined postmortem parent drug to metabolite concentration ratios of four 
commonly encountered opioids at least partially metabolized by the cytochrome P450 
enzyme system, fentanyl/norfentanyl, hydrocodone/dihydrocodeine, methadone/EDDP, and 
oxycodone/oxymorphone, in the presence and absence of two commonly identified co-
intoxicant benzodiazepines, alprazolam, and diazepam. It is hypothesized that with potential 
competition with or inhibition of CYP3A4 by alprazolam or diazepam, the opioid parent 
concentrations and parent to metabolite concentration ratios would be higher compared to 
the opioid alone. The findings will contribute to better understanding of possible interactions 
between benzodiazepines and opioids in unintentional drug-related deaths and will assist in 
the interpretation of parent opioid and metabolite concentrations during opioid-related death 
investigations.
 Materials and Methods
 Case Identification
A Forensic Drug Database (FDD) was initially created in 2005 to track and analyze data 
from all drug-related deaths in West Virginia. Pertinent death investigation data are entered 
directly into the FDD by the WV Office of the Chief Medical Examiner (OCME). These 
data include demographic information (age, gender, zip code location of death), condition of 
the body, body mass index, death certificate data (cause and manner of death, contributory 
factors to death, the drugs identified as a cause or contributor to the death), the known or 
suspected route of drug administration, whether the decedent had a prescription for any 
controlled substances identified (utilizing the West Virginia controlled substances 
monitoring program database), medical history (available for most decedents), key autopsy 
findings (all decedents), and toxicological analyses (all drug-related deaths). At the time of 
this study, the database contained information on 2784 drug-related deaths that occurred 
from January 2005 through most of 2010 (data entry ongoing).
For the study analyses, all accidental drug-related deaths involving four or less concomitant 
drugs were identified. Cases were excluded that involved more than four co-intoxicant drugs 
to minimize the possibility of confounding effects. Of the remaining cases, those in which 
fentanyl, hydrocodone, methadone, or oxycodone were determined to have caused or 
contributed to the death were identified. Cases were excluded if more than one opioid was 
identified by toxicological analyses or if benzodiazepines other than alprazolam or diazepam 
were present. This resulted in the dataset used for the parent opioid concentration analyses 
by number of drugs present (Group A). For the parent opioid and parent to metabolite opioid 
concentration ratio analyses in the presence or absence of alprazolam and diazepam, cases 
involving contributory co-intoxicants that are inhibitors or inducers of CYP3A4 or CYP2D6 
or that have known pharmacokinetic interactions with opioids were also excluded (Group 
B).
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Study cases were autopsied by the West Virginia Office of the Chief Medical Examiner, and 
blood (subclavian, femoral, iliac, and/or heart), liver, gastric contents, vitreous fluid, and 
urine (or aqueous bladder rinse) samples were typically obtained. All were analyzed for 
volatile compounds, including ethanol by GC-FID with t-butanol as internal standard. Blood 
or urine was screened by enzyme-multiplied immunoassay technique using reagents 
purchased from Microgenics-Thermo Scientific (Middletown, VA). The immunoassay test 
panel included amphetamine/methamphetamine, barbiturates, benzodiazepines, 
buprenorphine, cocaine metabolite, fentanyl, marijuana metabolite, methadone, opiates, 
oxycodone/oxymorphone, and tricyclic antidepressants. In preparation for immunoassay, a 
1.0 mL aliquot of blood was precipitated using acetone, inverted for 10 min, and centrifuged 
at 3000 × g. The organic layer was then dried at 37°C under a stream of nitrogen gas. The 
resultant extract was reconstituted using deionized water. Drug screening of protein-
precipitated blood extracts was also performed beginning in 2009–2010 using LC/TOF-MS 
or LC-MS/MS. Confirmation and quantitation of positive screen results were performed 
using LC-MS or LC-MS/MS with deuterated internal standards or GC/MS with proadifen or 
barbital as internal standards.
 Statistical Analyses
Cochran–Mantel–Haenszel tests were used to compare age distribution, gender, number of 
concomitant drugs present, and benzodiazepine usage (i.e., neither, alprazolam, diazepam, or 
both) among the opioid groups. Kruskal–Wallis tests were performed to analyze differences 
in parent opioid concentrations based upon the presence or absence of benzodiazepines and 
number of concomitant drugs present and also to compare parent to metabolite concentration 
ratios for each opioid in the presence and absence of alprazolam and diazepam. For overall 
statistically significant opioid concentration comparisons, post hoc pairwise Wilcoxon rank-
sum tests were performed. The level of significance of each pairwise test was reduced from 
0.05 to 0.0083 (0.05/6) using the conservative Bonferroni correction to reduce the likelihood 
of Type I error with the multiple pairwise comparisons. All of the data analyses were carried 
out in SAS version 9.3 (SAS Institute, Cary, NC).
 Results
 Parent Opioid and Drug/Metabolite Concentrations
Of the 2355 accidental drug-related deaths in the FDD, 877 fatalities were included in Group 
A and 349, all of which had metabolite concentrations, were included in Group B. Figure 1 
provides a flow chart for those cases included in the opioid parent drug concentration 
analyses (Group A) and those cases in the opioid parent and parent to metabolite 
concentration ratio analyses that excluded deaths in which known opioid drug–drug 
interactions or alcohol was present (Group B).
Of the single opioid-related deaths involving fentanyl, hydrocodone, methadone, or 
oxycodone, methadone was most often present, followed by oxycodone, and hydrocodone 
and fentanyl (Table 1). Most of these deaths occurred in males with an approximate 2:1 ratio 
between male and female decedents across all four opioid groups. Most decedents were aged 
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26 to 44 years (constituting from 42% to 56% of decedents) for each opioid present, with 45 
to 54 years of age being the next most prevalent group. The age distributions were similar 
between fentanyl and oxycodone. However, the ages of decedents who ingested 
hydrocodone were statistically significantly different compared to the other three opioids, 
with 52.6% of these individuals being 45 years of age and older, compared to 27–40.3% for 
the decedents ingesting fentanyl, methadone, or oxycodone. Methadone decedents were 
significantly younger than those ingesting hydrocodone, fentanyl, or oxycodone, with 73% 
of those who used methadone being 44 years of age or younger, compared to ranges of 
approximately 47% (hydrocodone) to 67% (fentanyl) for the other opioids in that age range.
Other drugs were frequently identified as contributors to the opioid-related deaths, with a 
single opioid present in only approximately 9–27% of cases. Hydrocodone was statistically 
significantly less likely to be present alone compared to the other three opioids. 
Benzodiazepines (alprazolam and diazepam) were often found in combination with one of 
the opioids, being present in from approximately 41% (methadone) to 68% (hydrocodone) 
of the Group A fatalities. The presence of benzodiazepines was statistically significantly 
different among the opioids, with alprazolam identified in almost double the proportion of 
hydrocodoneand oxycodone-related deaths as compared to the fentanyl- and methadone-
associated fatalities.
In general, as the number of identified drugs increased from 1 or 2 drugs present to 3 or 4 
drugs present, the median concentrations of hydrocodone, methadone, and oxycodone 
statistically significantly decreased (Table 2). The median drug concentrations were similar 
between cases in which only a single opioid was present and those fatalities in which an 
opioid and 1 other drug was present. Similar but significantly lower blood opioid 
concentrations were present when a total of three or four cointoxicants were identified. No 
statistically significant relationship was found among the median fentanyl blood 
concentrations and the number of drugs present, with the concentrations similar across 
categories.
Median opioid parent and parent/metabolite concentration ratios for Group B deaths in the 
presence and absence of alprazolam and/or diazepam are shown in Table 3. There were no 
statistically significant differences in the median parent drug or the median parent to 
metabolite blood concentration ratios for fentanyl or oxycodone regardless of the presence/
absence of benzodiazepines. Median fentanyl concentrations in particular were identical 
regardless of whether one or both benzodiazepines were present or absent. There was a 
statistically significant difference overall among the median hydrocodone parent drug 
concentrations in the presence/absence of a benzodiazepine (Table 3). This was statistically 
significant for hydrocodone alone (0.31 μg/mL) versus hydrocodone with both alprazolam 
and diazepam present (0.16 μg/mL; pairwise Wilcoxon rank-sum; p = 0.01); however, this 
comparison was nonsignificant (p = 0.06) after the conservative Bonferroni correction was 
applied.
There was no statistically significant difference among the median parent methadone 
concentrations in the presence or absence of a benzodiazepine (Table 3). There was a 
significant difference overall among the median methadone parent to metabolite 
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concentration ratios (Table 3); this was statistically significant for the median ratio with 
methadone alone (11.85) versus the ratio in the presence of diazepam (7.67; pairwise 
Wilcoxon rank-sum; p < 0.04 with Bonferroni correction).
 Discussion
Previous studies have found co-intoxicants to be frequently involved in opioid-related 
deaths, with benzodiazepines identified in 11–86% of these fatalities (5,6,12,13,15–25). The 
present analysis similarly found that single opioid fentanyl-, hydroco-done-, methadone-, 
and oxycodone-related deaths were uncommon, with concomitant be nzodiazepines present 
in 41% to 68% of these deaths. Hydrocodone-related deaths were most likely and 
methadone-related deaths were least likely to have at least one benzodiazepine present. 
Alprazolam was more often identified in the hydrocodone- and oxycodone-associated deaths 
than in the fentanyl- and methadone-related fatalities.
The 95th percentile opioid concentrations in this study were generally much higher and 
demonstrated greater variability than the median values, likely indicative of skewed 
concentration data. Thus, medians were used for statistical comparisons as has been 
recommended by others (44,45). Previous studies have reported significantly lower 
oxycodone blood concentrations when multiple drugs were involved in the deaths, compared 
to single oxycodone-related deaths (44,46), indicating the potential for toxic interactions 
among these drugs. The present study found significant reductions in median blood 
concentrations for hydrocodone, methadone, and oxycodone when 3 or 4 drugs were 
identified compared to when only one or two drugs were involved. Thus, lower opioid 
concentrations might be needed to achieve the threshold for fatal intoxication in the presence 
of multiple co-intoxicants. Interestingly, median fentanyl concentrations were not 
significantly affected by an increasing number of co-intoxicant drugs. The reason for this 
difference is unknown and should be verified using a larger number of fentanyl cases.
In the presence of benzodiazepines that might inhibit CYP3A4, diminished metabolism of 
opioids affected by that enzyme might result in higher parent opioid concentrations as well 
as higher parent/metabolite concentration ratios. The present study did not find statistically 
significant differences among the median opioid concentrations in the presence or absence 
of a benzodiazepine, with the exception of an overall significant reduction in hydrocodone 
concentrations alone compared to hydrocodone concentrations in the presence of both 
alprazolam and diazepam, although the statistical significance was lost when a multiple 
comparison correction was used. Deaths in which any co-intoxicant drug was present that 
was a known inhibitor or inducer of CYP3A4 or CYP2D6, or was otherwise documented to 
affect the concentrations of the opioids studied, were excluded so that any effect observed 
would be more likely to result from the benzodiazepines. Certain aspects of hydrocodone 
metabolism in humans are not fully understood. This adds to the complexity of interpreting 
parent and metabolite drug concentrations in postmortem cases where several other 
confounding factors might exist.
Inconsistent effects of benzodiazepines on opioid concentrations have been reported in the 
literature. Two studies in living subjects (41,42) demonstrated similar results to the present 
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study, with no effect on methadone concentrations evident in the presence of diazepam. A 
case series by Rogers et al., found that the postmortem blood methadone concentrations 
(0.14–0.70 mg/L) in cases involving co-administration of methadone and alprazolam were 
lower than literature reports for single drug overdoses (0.4–1.8 mg/L and 122–390 μg/L) 
(47). In contrast, Andreassan et al. studied factors that might influence oxycodone 
pharmacokinetics and found that use of a CYP3A4 inhibitor (i.e., fluconazole, 
clarithromycin, verapamil, nelfinavir, itraconazole, and diltiazem) increased oxycodone 
serum concentrations (48). Although this study does not provide support for a 
pharmacokinetic interaction between the opioids and benzodiazepines studied, an enhanced 
pharmacological effect could be responsible for lower opioid concentrations observed when 
opioids and benzodiazepines are co-ingested. Other studies have speculated that concomitant 
opioid–psychotropic medication ingestion can lead to an additive pharmacological effect 
with respiratory depression occurring at lower opioid doses (11,13,19,44,47,49,50).
The drug/metabolite ratio has been proposed as a marker reflecting recent opioid use and the 
likelihood of a period of abstinence (51). A low metabolite to parent concentration ratio 
suggests acute consumption. By contrast, when low parent drug/ metabolite concentration 
ratios are observed, longer term opioid use may be inferred. In this study, the only 
statistically significant difference seen in the median opioid parent to metabolite 
concentration ratio in the presence of a benzodiazepine was for the methadone ratio in the 
presence of diazepam, which was reduced by approximately 35% compared to methadone 
alone. Methadone/EDDP concentration ratios ranging from 0.1 to 60 have been reported in 
the literature (10,52,53). Our methadone ratios in the presence and absence of 
benzodiazepines fell within this range. Buchard et al. measured both R- and S-enantiomers 
of methadone and its metabolite, EDDP, in 90 postmortem cases and found no evidence that 
drug–drug interactions influenced the ratio of methadone to metabolite for either enantiomer 
for comparisons among methadone only, methadone and another strong analgesic, 
methadone and a benzodiazepine, and methadone and other drugs (10). In our study, chronic 
use of methadone may have contributed to the lower parent/metabolite concentration ratio 
observed with diazepam. Alternatively, due to the complex metabolism of methadone, the 
presence of a benzodiazepine may have minimal pharmacokinetic effects on the opioid.
There were several potential limitations to this study. While efforts were made to be 
complete and accurate when entering relevant information from each fatality into the FDD, 
it is possible that some errors were made during data entry. Some data related to drug 
concentrations were either not obtained for a decedent or not available in their file; these 
cases, relatively small in number, were excluded. The amount of drug actually taken in most 
fatalities cannot be accurately established, and the route of administration might not be 
definitively known. Although we eliminated fatalities with co-intoxicants that were known 
to be inducers/inhibitors of CYP 3A4 or 2D6 or were documented to affect opioid 
pharmacokinetics, it is possible that some inhibitors or inducers of CYP metabolism that are 
not identified during toxicological testing (e.g., St. John's Wart, azole antifungals, grapefruit 
juice) were present in decedents. A variety of other factors may affect postmortem drug 
concentrations in drug-related deaths including age, gender, body mass index, organ 
function, the postmortem interval, and genetic variability (54). Certain CYP enzymes, 
particularly CYP2D6, show genetic variation which leads to interindividual differences in 
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therapeutic response and adverse side effects (55). The increased risk of methadone 
mortality has been associated with the CYP2B6*6 allele (56). Co-administration of 
methadone and benzodiazepines can be toxic in the presence of gene variation 
OPRM1A118g (56). Pharmacogenomics testing was not conducted on samples. Given the 
association between ethnicity and pharmacogenomics, this variable may provide a potential 
explanation for the differences in the ratios of drug/metabolites. The small sample size for 
some of the individual groups analyzed, particularly for Group B, could have impacted the 
study's power. A limitation of postmortem data collection is that some drugs undergo 
extensive postmortem redistribution. This is of greater concern for highly lipophilic drugs 
such as methadone, fentanyl, and drugs with large volumes of distribution (31,57). In this 
study, drug concentration measurements were obtained using blood from the subclavian or 
femoral vein. As heart blood is most susceptible to artifactual changes after death (22), a 
small number of overdose deaths were excluded in which peripheral blood was unavailable 
and heart blood or tissues were used for the toxicological analyses.
 Conclusion
Analysis of 877 drug-related deaths found that the presence of 3 or 4 co-intoxicants 
significantly decreased hydrocodone, methadone, and oxycodone, but not fentanyl, parent 
drug concentrations compared to when these opioids were present alone or combined with 1 
other drug. Median opioid concentrations were not statistically significantly affected by the 
presence or absence of diazepam or alprazolam, with the possible exception of hydro-
codone. The presence of diazepam significantly decreased the methadone parent drug/
metabolite concentration ratio compared to methadone alone. Further research examining 
drug concentrations from larger numbers of accidental opioid-related deaths is warranted to 
determine if significant differences exist between individual opioids in the presence of 
specific co-intoxicants. Decedent characteristics or combinations of factors that might affect 
postmortem opioid concentrations and their potential toxicity should also be explored.
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TABLE 1
Decedent characteristics of cases analyzed (Group A).
Opioid
Characteristic Fentanyl (n = 135) Hydrocodone (n = 135) Methadone (n = 337) Oxycodone (n = 270) p Value
Age, n (%)
    ≤25 15 (11.1) 8 (5.9) 81 (24) 35 (13)
<0.001
*,‡
    26–44 75 (55.6) 56 (41.5) 165 (49) 126 (46.7)
    45–54 37 (27.4) 52 (38.5) 80 (23.7) 87 (32.2)
    55–74 8 (5.9) 19 (14.1) 11 (3.3) 22 (8.1)
Gender, n (%)
    Male 86 (63.7) 87 (64.4) 246 (73) 188 (69.6) 0.13
    Female 49 (36.3) 48 (35.6) 91 (27) 82 (30.4)
Benzodiazepine, n (%)
    Neither 76 (56.3) 43 (31.9) 200 (59.3) 108 (40)
<0.001
†,‡
    Alprazolam 18 (13.3) 47 (34.8) 59 (17.5) 90 (33.3)
    Diazepam 23 (17) 25 (18.5) 65 (19.3) 44 (16.3)
    Both 18 (13.3) 20 (14.8) 13 (3.9) 28 (10.4)
Number of drugs present, n (%)
    1 29 (21.5) 12 (8.9) 92 (27.3) 48 (17.8)
<0.001
*,‡
    2 47 (34.8) 52 (38.5) 150 (44.5) 125 (46.3)
    3 40 (29.6) 50 (37.0) 73 (21.7) 73 (27.0)






Pairwise opioid comparisons (Bonferroni correction): Age – All statistically significant (p < 0.04) except fentanyl versus oxycodone (p = 1). 
Benzodiazepines – All statistically significant (p < 0.015) except hydrocodone versus oxycodone (p = 1). Number of drugs present – All 
statistically significant (p < 0.03) except fentanyl versus hydrocodone, oxycodone (p > 0.2).
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TABLE 2
Parent drug concentrations by number of drugs involved (Group A).
Parent Drug Concentration
Opioid Median (μg/mL) 95th percentile (μg/mL) p-Value
Fentanyl
# drugs present (n, %)
    1 (29, 16.3%) 0.015 0.076 0.3135
    2 (47, 34.8%) 0.016 0.066
    3 (40, 29.6%) 0.011 0.043
    4 (19, 14.1%) 0.013 0.049
Hydrocodone
# drugs present (n, %)
    1 (12, 8.9%) 0.27 1.20
0.0002
*
    2 (52, 38.5%) 0.20 0.67
    3 (50, 37%)
0.13
‡ 0.53




# drugs present (n, %)
    1 (92, 27.2%) 0.42 1.36
0.0073
*
    2 (150, 44.5%) 0.42 1.47
    3 (73, 21.7%) 0.38 0.87




# drugs present (n, %)
    1 (48, 17.8%) 0.52 1.62
0.0046
*
    2 (125, 46.3%) 0.40 1.45
    3 (73, 27%)
0.27
† 0.92
    4 (24, 8.9%) 0.26 1.31
*
Statistically significant differences among median values; Kruskal–Wallis.
†
Statistically significant (p < 0.05) compared to 1 or 2 drugs; post hoc pairwise Wilcoxon rank-sum.
‡
Statistically significant (p < 0.05) compared to 1 drug; post hoc pair-wise Wilcoxon rank-sum.
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TABLE 3
Parent drug concentrations and parent/metabolite ratios in presence/absence of alprazolam and diazepam 
(Group B).




Parent Drug Concentration Parent/Metabolite Concentration Ratio
Median (μg/mL) 95th Percentile (μg/mL)
p-Value




    A (12, 21.4%) 0.01 0.07 0.80 3.64 9.33 0.52
    D (5, 8.9%) 0.01 0.03 1.73 13.00
    A + D (11, 19.6%) 0.01 0.03 3.45 7.06
    Neither (28, 50%) 0.01 0.06 4.13 25.27
Hydrocodone (49)
    A (23, 46.9%) 0.20 0.50
0.02
‡ 4.50 22.5 0.06
    D (6, 12.2%) 0.38 1.30 3.01 8.13
    A + D (10, 20.4%) 0.16 0.30 3.17 7.00
    Neither (10, 20.4%) 0.31 1.20 8.11 20.00
Methadone (166)
    A (31, 18.7%) 0.44 1.44 0.10 8.50 26.00
0.01
‡
    D (35, 21.1%) 0.39 1.17 7.67 23.00
    A + D (6, 3.6%) 0.73 1.04 6.94 12.43
    Neither (94, 56.6%) 0.50 1.50 11.85 48.40
Oxycodone (78)
    A (26, 33.3%) 0.44 1.50 0.45 7.80 44.00 0.14
    D (10, 12.8%) 0.40 1.69 10.48 83.00
    A + D (11, 14.1%) 0.40 1.13 3.53 23.00
    Neither (31, 39.7%) 0.51 1.45 3.91 18.40
*
Differences among median values.
†
A = alprazolam, D = diazepam, A + D = alprazolam and diazepam.
‡
Statistically significant; Kruskal–Wallis.
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